Epidemiology of Travel-Associated Dengue from 2007 to 2022: A GeoSentinel Analysis.

Dengue Dengue virus GeoSentinel epidemiology travellers

Journal

Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456

Informations de publication

Date de publication:
02 Jul 2024
Historique:
received: 05 05 2024
revised: 25 06 2024
accepted: 28 06 2024
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 2 7 2024
Statut: aheadofprint

Résumé

Dengue is a leading cause of febrile illness among international travellers. We aimed to describe the epidemiology and clinical characteristics of imported dengue in returning travellers evaluated at GeoSentinel sites from 2007-2022. We retrieved GeoSentinel records of dengue among travellers residing in non-endemic countries. We considered dengue confirmed when diagnosed by a positive DENV-specific RT-PCR, positive NS-1 antigen, and/or anti-DENV IgG seroconversion, and probable when diagnosed by single anti-DENV IgM or high titre anti-DENV IgG detection. Severe dengue was defined as evidence of clinically significant plasma leakage or bleeding, organ failure, or shock, according to the 2009 WHO guidance. Complicated dengue was defined as either severe dengue or dengue with presence of any warning sign. Analyses were descriptive. This analysis included 5958 travellers with confirmed (n = 4859; 81.6%) or probable (n = 1099; 18.4%) dengue. The median age was 33 years (range: < 1-91); 3007 (50.5%) travellers were female. The median travel duration was 21 days (interquartile range [IQR]: 15-32). The median time between illness onset and GeoSentinel site visit was 7 days (IQR: 4-15). The most frequent reasons for travel were tourism (67.3%), visiting friends or relatives (12.2%), and business (11.0%). The most frequent regions of acquisition were Southeast Asia (50.4%), South-Central Asia (14.9%), the Caribbean (10.9%), and South America (9.2%). Ninety-five (1.6%) travellers had complicated dengue, of whom 27 (0.5%) had severe dengue, and one died. Of 2710 travellers with data available, 724 (26.7%) were hospitalized. The largest number of cases (n = 835) was reported in 2019. A broad range of international travellers should be aware of the risk of acquiring dengue and receive appropriate pretravel counselling regarding preventive measures. Prospective cohort studies are needed to further elucidate dengue risk by destination and over time, as well as severe outcomes and prolonged morbidity (long-dengue) due to travel-related dengue.

Sections du résumé

BACKGROUND BACKGROUND
Dengue is a leading cause of febrile illness among international travellers. We aimed to describe the epidemiology and clinical characteristics of imported dengue in returning travellers evaluated at GeoSentinel sites from 2007-2022.
METHODS METHODS
We retrieved GeoSentinel records of dengue among travellers residing in non-endemic countries. We considered dengue confirmed when diagnosed by a positive DENV-specific RT-PCR, positive NS-1 antigen, and/or anti-DENV IgG seroconversion, and probable when diagnosed by single anti-DENV IgM or high titre anti-DENV IgG detection. Severe dengue was defined as evidence of clinically significant plasma leakage or bleeding, organ failure, or shock, according to the 2009 WHO guidance. Complicated dengue was defined as either severe dengue or dengue with presence of any warning sign. Analyses were descriptive.
RESULTS RESULTS
This analysis included 5958 travellers with confirmed (n = 4859; 81.6%) or probable (n = 1099; 18.4%) dengue. The median age was 33 years (range: < 1-91); 3007 (50.5%) travellers were female. The median travel duration was 21 days (interquartile range [IQR]: 15-32). The median time between illness onset and GeoSentinel site visit was 7 days (IQR: 4-15). The most frequent reasons for travel were tourism (67.3%), visiting friends or relatives (12.2%), and business (11.0%). The most frequent regions of acquisition were Southeast Asia (50.4%), South-Central Asia (14.9%), the Caribbean (10.9%), and South America (9.2%). Ninety-five (1.6%) travellers had complicated dengue, of whom 27 (0.5%) had severe dengue, and one died. Of 2710 travellers with data available, 724 (26.7%) were hospitalized. The largest number of cases (n = 835) was reported in 2019.
CONCLUSIONS CONCLUSIONS
A broad range of international travellers should be aware of the risk of acquiring dengue and receive appropriate pretravel counselling regarding preventive measures. Prospective cohort studies are needed to further elucidate dengue risk by destination and over time, as well as severe outcomes and prolonged morbidity (long-dengue) due to travel-related dengue.

Identifiants

pubmed: 38951998
pii: 7702467
doi: 10.1093/jtm/taae089
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Published by Oxford University Press on behalf of International Society of Travel Medicine 2024.

Auteurs

Alexandre Duvignaud (A)

Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.
Global Health in the Global South - University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219 - Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.

Rhett J Stoney (RJ)

Division of Global Migration Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Kristina M Angelo D O (KM)

Division of Global Migration Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lin H Chen (LH)

Division of Infectious Diseases and Travel Medicine, Mount Auburn Hospital, Cambridge, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Paolo Cattaneo (P)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

Leonardo Motta (L)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

Federico G Gobbi (FG)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Emmanuel Bottieau (E)

Department of Clinical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, Antwerp 2000, Belgium.

Daniel L Bourque (DL)

Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.

Corneliu P Popescu (CP)

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Dr Victor Babeș Clinical Hospital and Infectious Diseases, Bucharest, Romania.

Hedvig Glans (H)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddingue, Division of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.

Hilmir Asgeirsson (H)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddingue, Division of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.

Ines Oliveira-Souto (I)

Vall d'Hebron-Drassanes International Health Unit, Infectious Diseases Department, Vall d'Hebron University Hospital, International Health Programme of Catalan Health Institute (PROSICS), Barcelona, Spain.
Centres, Services and Reference Units (CSUR) Imported Tropical Diseases, Barcelona, Spain.
Centre for Biomedical Research Network on Infectious Diseases, Madrid, Spain.

Stephen D Vaughan (SD)

Department of Medicine, Division of Infectious Diseases, University of Calgary, Calgary, AB, Canada.

Bhawana Amatya (B)

CIWEC Hospital and Travel Medicine Center, Lainchaur, Kathmandu, Nepal.

Francesca F Norman (FF)

National Referral Unit for Tropical Diseases, Infectious Diseases Department, Ramón y Cajal University Hospital, CIBERINFEC, IRYCIS, Madrid, Spain.
Universidad de Alcalá, Madrid, Spain.

Jesse Waggoner (J)

Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia.

Marta Diaz-Menendez (M)

Tropical Medicine Department, Hospital Universitario La Paz-Carlos III, IdIPAz, and CIBERINFECT, Madrid, Spain.

Michael Beadsworth (M)

Tropical and infectious Disease Unit, Royal Liverpool University Hospital; Liverpool University Hospitals Foundation Trust, Liverpool, UK.

Silvia Odolini (S)

University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.

Daniel Camprubí-Ferrer (D)

ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Loic Epelboin (L)

Infectious and Tropical Diseases Unit and CIC Inserm 1424, Centre Hospitalier de Cayenne, Cayenne, French Guiana.

Bradley A Connor (BA)

Weill Cornell Medical College and the New York Center for Travel and Tropical Medicine, New York, NY, USA.

Gilles Eperon (G)

Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland.

Eli Schwartz (E)

The Center of Geographical Medicine and Tropical Diseases, Sheba Medical Center, Street Ramat Gan, Tel HaShomer, Israel.
Ramat Gan & Sackler Faculty of Medicine, Tel Aviv University, Rehov Klatskin 23, Tel Aviv, Israel.

Michael Libman (M)

Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada.
J.D. MacLean Centre for Tropical Diseases at McGill University, Montréal, Québec, Canada.

Denis Malvy (D)

Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.
Global Health in the Global South - University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219 - Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.

Davidson H Hamer (DH)

Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
Center for Emerging Infectious Disease Policy and Research, Boston University, Boston, MA, USA.
National Emerging Infectious Disease Laboratory, Boston, Massachusetts, USA, Boston, MA, USA.

Ralph Huits (R)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

Classifications MeSH